TY - GEN
T1 - Sustained-released platelet-rich plasma from polyethylene glycol hydrogels exerts beneficial effects on chondrocytes
AU - Blanco, A.
AU - Jain, E.
AU - Chinzei, N.
AU - Case, N.
AU - Sell, S. A.
AU - Rai, M. F.
AU - Zustiak, S. P.
N1 - Publisher Copyright:
© 2019 Omnipress - All rights reserved.
PY - 2019
Y1 - 2019
N2 - Statement of Purpose: Osteoarthritis (OA), a disease caused by chronic inflammation and wearing of articular cartilage, affects more than 50 million Americans. Currently available clinical treatments for this disease fail to suppress cartilage degeneration or synovial inflammation, or to promote tissue regeneration. Platelet-rich plasma (PRP) therapy involves a direct injection of PRP into the joint cavity. PRP is obtained by drawing patients own blood and concentrating platelets, which release bioactive factors that are critical to tissue regeneration and cellular recruitment. However, current strategies utilizing bolus injections of PRP remain ineffective due to a rapid clearance of growth factors. A sustained-release injectable formulation of PRP would be beneficial by maintaining a steady amount of the bioactive factors at the site of injury. Thus, in this study, we test therapeutic effects of sustained-released PRP, encapsulated as lyophilized powder (PRGF), from polyethylene glycol (PEG) hydrogels in vitro on human chondrocytes and tissue explants.
AB - Statement of Purpose: Osteoarthritis (OA), a disease caused by chronic inflammation and wearing of articular cartilage, affects more than 50 million Americans. Currently available clinical treatments for this disease fail to suppress cartilage degeneration or synovial inflammation, or to promote tissue regeneration. Platelet-rich plasma (PRP) therapy involves a direct injection of PRP into the joint cavity. PRP is obtained by drawing patients own blood and concentrating platelets, which release bioactive factors that are critical to tissue regeneration and cellular recruitment. However, current strategies utilizing bolus injections of PRP remain ineffective due to a rapid clearance of growth factors. A sustained-release injectable formulation of PRP would be beneficial by maintaining a steady amount of the bioactive factors at the site of injury. Thus, in this study, we test therapeutic effects of sustained-released PRP, encapsulated as lyophilized powder (PRGF), from polyethylene glycol (PEG) hydrogels in vitro on human chondrocytes and tissue explants.
UR - http://www.scopus.com/inward/record.url?scp=85065425439&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:85065425439
T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
SP - 517
BT - Society for Biomaterials Annual Meeting and Exposition 2019
PB - Society for Biomaterials
T2 - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
Y2 - 3 April 2019 through 6 April 2019
ER -